Obesity Prevalence and Health Risks in 2024
The U.S. adult obesity rate reached 42.4% according to the latest CDC data, with severe obesity affecting about 9.2% of adults. Obesity increases the risk of heart disease, type 2 diabetes, stroke, and certain cancers. The CDC reports that medical costs for people with obesity are significantly higher than for those with a healthy weight, making effective help with weight loss a public health priority. CDC obesity data shows that these rates have remained high in recent years.
Globally, the World Health Organization estimates that over 1 billion people live with obesity, a figure that has tripled since 1975. The WHO links excess body weight to a higher risk of hospitalization and mortality from conditions including cardiovascular disease and diabetes. These statistics underscore why health systems and insurers are prioritizing scalable help with weight loss interventions. WHO obesity fact sheet provides the latest global estimates.
GLP-1 Medications and Clinical Weight Loss Results
GLP-1 receptor agonists such as semaglutide and tirzepatide have become a major focus in clinical help with weight loss. In phase 3 trials, participants using semaglutide at a 2.4 mg dose achieved an average weight loss of about 14.9% of initial body weight over 68 weeks. Tirzepatide trials showed average reductions of up to 20.9% depending on dosage. The FDA approved these medications for chronic weight management in adults with obesity or overweight with at least one weight-related condition. FDA drug approvals include detailed prescribing information for these therapies.
Pharmaceutical companies including Eli Lilly and Novo Nordisk have expanded manufacturing capacity to meet demand for these medications. Eli Lilly's tirzepatide, sold under the brand name Mounjaro for metabolic health and Zepbound for weight management, received FDA approval in late 2023. Novo Nordisk's Wegovy, a semaglutide-based treatment, was approved for weight management in 2021. Coverage policies vary by insurer, with many requiring documented obesity or weight-related conditions before approval. SEC filings from these companies report quarterly sales and production updates.
Digital Weight Management Programs and Behavioral Tools
Digital health platforms now offer structured programs for help with weight loss that combine coaching, food tracking, and behavioral science. Companies like Noom and WW (formerly Weight Watchers) use cognitive behavioral techniques to address eating patterns and adherence. Noom reported that in a published study, participants lost an average of 6.4% of their starting weight over 16 weeks using the app-based program. WW's corporate program includes personalized plans and digital workshops, with peer-reviewed studies showing clinically meaningful weight reductions over 12 months. Forbes health coverage regularly reviews the evidence behind these commercial platforms.
Wearable devices and continuous glucose monitors are increasingly integrated into weight management plans to provide real-time feedback on activity and metabolic responses. Companies such as Fitbit and Dexcom supply data that clinicians use to tailor nutrition and exercise recommendations. Research published in journals including Obesity and The Lancet Digital Health shows that combining wearable data with coaching improves weight loss outcomes compared with self-directed efforts. Tesla's health-related data partnerships and